1. Home
  2. DSU vs REPL Comparison

DSU vs REPL Comparison

Compare DSU & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DSU
  • REPL
  • Stock Information
  • Founded
  • DSU 1998
  • REPL 2015
  • Country
  • DSU United States
  • REPL United States
  • Employees
  • DSU N/A
  • REPL N/A
  • Industry
  • DSU Finance Companies
  • REPL Biotechnology: Pharmaceutical Preparations
  • Sector
  • DSU Finance
  • REPL Health Care
  • Exchange
  • DSU Nasdaq
  • REPL Nasdaq
  • Market Cap
  • DSU 548.1M
  • REPL 547.0M
  • IPO Year
  • DSU N/A
  • REPL 2018
  • Fundamental
  • Price
  • DSU $10.61
  • REPL $5.67
  • Analyst Decision
  • DSU
  • REPL Hold
  • Analyst Count
  • DSU 0
  • REPL 9
  • Target Price
  • DSU N/A
  • REPL $7.00
  • AVG Volume (30 Days)
  • DSU 148.2K
  • REPL 2.1M
  • Earning Date
  • DSU 01-01-0001
  • REPL 11-11-2025
  • Dividend Yield
  • DSU 10.06%
  • REPL N/A
  • EPS Growth
  • DSU N/A
  • REPL N/A
  • EPS
  • DSU N/A
  • REPL N/A
  • Revenue
  • DSU N/A
  • REPL N/A
  • Revenue This Year
  • DSU N/A
  • REPL N/A
  • Revenue Next Year
  • DSU N/A
  • REPL $408.25
  • P/E Ratio
  • DSU N/A
  • REPL N/A
  • Revenue Growth
  • DSU N/A
  • REPL N/A
  • 52 Week Low
  • DSU $9.22
  • REPL $2.68
  • 52 Week High
  • DSU $11.40
  • REPL $17.00
  • Technical
  • Relative Strength Index (RSI)
  • DSU 55.06
  • REPL 46.30
  • Support Level
  • DSU $10.52
  • REPL $5.74
  • Resistance Level
  • DSU $10.64
  • REPL $6.15
  • Average True Range (ATR)
  • DSU 0.06
  • REPL 0.34
  • MACD
  • DSU 0.00
  • REPL 0.09
  • Stochastic Oscillator
  • DSU 70.83
  • REPL 29.06

About DSU Blackrock Debt Strategies Fund Inc.

Blackrock Debt Strategies Fund Inc is a diversified, closed-end management investment company. Its investment objective is to provide current income by investing in a diversified portfolio of U.S. companies' debt instruments including corporate loans. The fund's secondary investment objective is to provide capital appreciation.

About REPL Replimune Group Inc.

Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.

Share on Social Networks: